Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | KIF11 | P52732 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL717273 | 1.00 | MAPT (0.44) | MAPTHTTKMT2AMEN1RAB9A | |
| SCHEMBL719029 | 1.00 | MAPT (0.44) | MAPTHTTKMT2AMEN1RAB9A | |
| SCHEMBL7904824 | 0.83 | RXFP1 (0.48) | MAPTHTTKMT2ACES2ALDH1A1 | |
| SCHEMBL7910019 | 0.83 | RXFP1 (0.48) | MAPTHTTKMT2ACES2ALDH1A1 | |
| SCHEMBL7907797 | 0.83 | RXFP1 (0.48) | MAPTHTTKMT2ACES2ALDH1A1 | |
| SCHEMBL15955100 | 0.82 | MAPT (0.57) | MAPTHTTKMT2AKIF11 | |
| SCHEMBL5220073 | 0.81 | GAA (0.50) | MAPTHTTKMT2AMEN1RAB9A | |
| SCHEMBL31691810 | 0.77 | MAPT (0.60) | MAPTHTTKMT2ACES2ALDH1A1 | |
| SCHEMBL22655989 | 0.77 | MAPT (0.60) | MAPTHTTKMT2ACES2ALDH1A1 | |
| SCHEMBL25408879 | 0.76 | PDE2A (0.45) | MAPTHTTKMT2AMEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053218-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN-RECEPTOR INHIBITORS FOR TREATING CARDIAC INSUFFICIENCY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053218-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN-RECEPTOR INHIBITORS FOR TREATING CARDIAC INSUFFICIENCY | AVPR2, AVPR1B, AVPR1A | MAPT 4521/4885HTT 3507/4885KMT2A 4765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.